- Home
- CGEM vs NEWP Comparison
CGEM vs NEWP Comparison
Compare CGEM & NEWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGEM | NEWP |
|---|---|---|
| Founded | 2016 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 948.3M |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CGEM | NEWP |
|---|---|---|
| Price | $15.16 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $30.13 | $6.00 |
| AVG Volume (30 Days) | 998.3K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $1.31 |
| 52 Week High | $16.74 | $6.31 |
Technical Indicators
Market Signals| Indicator | CGEM | NEWP |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 41.46 |
| Support Level | $11.92 | $3.31 |
| Resistance Level | $16.21 | $5.79 |
| Average True Range (ATR) | 0.96 | 0.34 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 56.07 | 9.78 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.